Transforming growth factor-β1 (TGF-β1) has been used as a biomarker in disorders associated with pathologic fibrosis. However, plasma TGF-β1 assessment is confounded by the significant variation in reported normal values, likely reflecting variable release of the large pool of platelet TGF-β1 after blood drawing. Moreover, current assays measure only total TGF-β1, which is dominated by the latent form of TGF-β1 rather than the biologically active form. To address these challenges, we developed methodologies to prevent ex vivo release of TGF-β1 and to quantify active TGF-β1. We then used these techniques to measure TGF-β1 in healthy controls and patients with heart failure (HF) before and after insertion of left ventricular assist devices (LVAD). Total plasma TGF-β1 was 1.0 ± 0.60 ng/mL in controls and 3.76 ± 1.55 ng/mL in subjects with HF (P < 0.001), rising to 5.2 ± 2.3 ng/mL following LVAD placement (P = 0.006). These results were paralleled by the active TGF-β1 values; controls had 3-16 pg/mL active TGF-β1, whereas levels were 2.7-fold higher in patients with HF before, and 4.2-fold higher after, LVAD implantation. Total TGF-β1 correlated with levels of the platelet-derived protein thrombospondin-1 (r = 0.87; P < 0.001), suggesting that plasma TGF-β1 may serve as a surrogate indicator of in vivo platelet activation. von Willebrand factor high molecular weight multimers correlated inversely with TGF-β1 levels (r = −0.63; P = 0.023), suggesting a role for shear forces in loss of these multimers and platelet activation. In conclusion, accurate assessment of circulating TGF-β1 may provide a valuable biomarker for in vivo platelet activation and thrombotic disorders. (Translational Research 2018;192:15-29) Abbreviations: CAD = coronary artery disease; CHF = congestive heart failure; DCM = dilated cardiomyopathy; HF = heart failure; LV = left ventricle; LVAD = left ventricular-assist device; PAI-1 = plasminogen activator inhibitor-1; SMCA = single-molecule counting assay; TGF-β1 = transforming growth factor beta 1; TSP-1 = thrombospondin-1; vWf = von willebrand factor
INTRODUCTION
Transforming growth factor-β1 (TGF-β1) plays important roles in both normal biologic processes and promotion of pathologic fibrosis.
1 Elevated TGF-β1 levels have been reported in patients with a variety of disorders, including heart failure (HF), 2, 3 coronary artery disease, 4 aortic stenosis, 5 Marfan syndrome, 6 human immunodeficiency virus-associated cardiac fibrosis, 7 radiationinduced organ fibrosis, 8 and malignancies. 9 In fact, serum TGF-β1 has been proposed as a biomarker for monitoring patient prognoses, 10 and in animal models, inhibiting TGF-β1 reduces pathologic remodeling after myocardial infarction and cardiac fibrosis induced by multiple HF provocations. 11, 12 Despite TGF-β1's demonstrable importance in various biological and pathologic conditions, the challenges encountered in accurately measuring its level in plasma have impeded it becoming a valuable biomarker, including the huge variation in total TGF-β1 values, from <0.1 to >60 ng/mL, reported for normal controls in the literature. 13, 14 One major factor contributing to these variations is failure to recognize that standard blood drawing by venipuncture techniques and plasma preparation may cause ex vivo platelet activation. Platelets contain 40-100 times as much TGF-β1 as other cells, and generation of even small amounts of thrombin or shear force can activate platelets to release their granule contents, 15 including latent TGF-β1, which in turn can be activated by shear force as previously demonstrated by our group. 16, 17 Serum levels are easier to measure because they reflect contributions from both plasma and the much larger pool of TGF-β1 released from platelets. Interpreting serum levels is difficult, however, because variations in platelet count and platelet size, as well as degranulation during clotting, are all potential variables that can confound interpreting their significance.
Apart from confounding an accurate assessment of plasma TGF-β1, it is possible that shear generated in vivo by interventions such as the implantation of a left ventricular assist device (LVAD) with a spinning rotor could also both increase the release of latent TGF-β1 into the circulation and then activate latent TGF-β1. Because activated TGF-β1 may contribute to the pathophysiology of fibrosis associated with HF, it is potentially an important biomarker in this disorder.
Separate from preventing the release of latent TGF-β1 during the preanalytic phase involving blood collection and plasma preparation is the challenge of measuring low levels of active TGF-β1, the form of the molecule required to initiate signaling. To overcome these challenges in assessing the potential value of plasma TGF-β1 as a biomarker of disease, we combined improved preanalytical phase plasma preparation, to avoid the confounding effects of total TGF-β1 release from platelets, with development of a more sensitive assay that can measure picogram levels of active TGF-β1 using highsensitivity single-molecule counting assay (SMCA) technology. With these methods, we consistently documented very low levels of active TGF-β1 in plasma from healthy donors. These levels were elevated in patients with HF, with further increases after LVAD implantation. Accurate assessment of circulating TGF-β1 may prove a surrogate biomarker for platelet activation and pro-fibrotic conditions, including thromboembolic complications characteristic of LVADs and cardiac fibrosis associated with HF. In addition, because TGF-β1 has also been implicated in the pathophysiology of aortic stenosis, 5 malignancies, 9 and many other disorders, measurement of active TGF-β1 may be a valuable biomarker more generally.
MATERIALS AND METHODS

Antibodies and reagents.
A chicken polyclonal IgY antibody and 2 mouse monoclonal antibodies to TGF-β1 were obtained from R&D Systems. A goat polyclonal antibody to human platelet factor 4 (PF4) was obtained from Cell Sciences, and a mouse monoclonal antibody (mAb) to thrombosponidin-1 (TSP-1) was obtained from NeoMarkers-Thermo Fisher Scientific. All isotypematched secondary antibodies were obtained from Jackson ImmunoResearch Laboratories. All other reagents were described previously [16] [17] [18] [19] or from Sigma or Thermo Fisher Scientific.
Patients and controls. Informed consent was obtained from patients and/or healthy controls at the Columbia University Heart Transplantation Center, the Rockefeller University, and the Oklahoma Medical Research Foundation under protocols approved by the Institutional Review Boards of the respective institutions, conforming to the relevant ethical guidelines for human subject research. A total of 47 patients with HF were included, 33 in the cross-sectional substudy, and 14 in the longitudinal substudy in which samples were obtained both before and after LVAD implantation. All patients had stage D HF and all were New York Heart Association Class IV. The average left ventricular AT A GLANCE COMMENTARY Mancini D, et al.
Background
TGF-β1 has been implicated in the pathophysiology of heart failure (HR), but accurate measurement of plasma TGF-β1 has been difficult to achieve because it is present at low levels and variable release of platelet TGF-β1 can confound the interpretation.
Translational significance
We developed methods to overcome these challenges by improving sample preparation and employing a novel single-molecule counting assay. With these techniques we found elevated levels of both total and active TGF-β in the plasma of HF patients and these levels further elevated after insertion of a left ventricular assist device.
ejection fraction was 18 ± 6%. Twenty-four of 33 cross-sectional patients with HF were male, as were 13 of 14 longitudinal cohort patients (Table I) . A total of 19 patient samples in the longitudinal cohort were obtained, but 5 patients were excluded because their plasma samples contained elevated levels of PF4, implying in vitro release of platelet granule contents. 20, 21 Thus, 14 patients were studied before and after LVAD implantation (1 DuraHeart, 1 HeartWare, and 12 secondgeneration HeartMate-II). The 20 healthy controls (13 males) were on average 20 years younger than the patients with HF (39 ± 10 vs 59 ± 17 years of age). All post-LVAD samples were obtained within 1 week after LVAD implantation. Some pre-and/or post-LVAD paired values were missing because of either technical difficulties or lack of sufficient samples to perform assays.
Echocardiography and other procedures. Two-D transthoracic echocardiograms were performed on patients with HF before and after LVAD implantation. Standard echocardiography was performed with a Philips iE33, Sonos 7500, Sonos 5500 (Philips, Andover, MA), or Vivid I digital ultrasound system (GE VingMed Ultrasound, Horten, Norway). LV end-diastolic diameter, interventricular septal thickness, and posterior wall thickness were measured according to the recommendations of the American Society of Echocardiography. LV ejection fraction was calculated by the modified Simpson method.
Preparation of human plasma samples. Because measurement of plasma TGF-β1 can be confounded by in vitro release of TGF-β1 from platelets, as we have shown in mouse models, 18 we developed and validated procedures for blood drawing and plasma preparation in humans to prevent release of TGF-β1 during the preanalytical phase. Blood samples were collected from healthy volunteers into syringes containing sodium citrate (0.38% final concentration) or commercial vacuum tubes (Vaccutainer; BD BioSciences, Franklin Lakes, NJ) containing 1 of 4 different anticoagulants, sodium citrate, ethylenediaminetetraacetic acid, heparin, or a combination of citrate, theophylline, adenosine, and dipyridamole. Blood was centrifuged at either 3,000 g for 15 minutes at room temperature (RT) or at 12,000 g for 5 minutes at 4°C, either immediately or 2 hours after blood collection. In some cases, the platelet release reaction inhibitor PGE1 (1 µM) was added to the blood collection tube to prevent release of platelet granule contents.
We also assessed the effect of shear on release and activation of platelet-derived TGF-β1 in plasma. To induce in vitro release of TGF-β1, whole blood collected in 0.38% sodium citrate from healthy volunteers was subjected to a shear rate of 1,800 s
, which is within the range of the normal arterial shear rate, for 10 minutes in a cone and plate device. Samples were then centrifuged at 12,000 g for 5 minutes at 4°C, and the plasma was separated and subsequently subjected to a shear rate of 1,800 s −1 for another 2 hours. Total and active TGF-β1 were then measured by enzyme-linked immunosorbent assay (ELISA) as described below.
Blood was collected from patients with HF before and after LVAD implantation into vacuum tubes containing 3.2% buffered sodium citrate, distributed into 1.5 mL micro-centrifuge tubes (Eppendorf), and centrifuged at 12,000 g for 5 minutes at 4°C. Plasma was removed without stirring, vortexing, or vigorous pipetting using a wide bore transfer pipette (Evergreen Scientific), and aliquoted and frozen at −80°C until assayed.
Immunoblotting. Plasma samples were mixed with soduim dodecylsulfate sample buffer, heated to 100°C for 3 minutes, and electrophoresed in 8%-16% gradient Tris-glycine gels (Invitrogen, Carlsbad, CA). The proteins were transferred to a polyvinylidene difluoride membrane and allowed to react with antibodies to human PF4 and TSP-1. Bound antibody was detected with matching secondary antibodies conjugated to horseradish peroxidase using the enchanced chemiluminescence detection system (Amersham, Pittsburgh, PA). Band intensities were quantitated using image analysis software (National Institutes of Health-Scion Image; Scion, Frederick, MD).
Measurement of total and activated forms of TGF-β1 by
ELISA.
Total TGF-β1 by ELISA. Total TGF-β1 (latent + active) in human plasma was measured with a 2-antibody ELISA assay specific for the activated form of TGF-β1 Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; DCM, dilated cardiomyopathy.
(R&D Systems, Minneapolis, MN) after converting latent TGF-β1 to active TGF-β1 by acidification (20-minute incubation at RT with 0.5 volume of 1 N HCl followed by neutralization with the same volume of 1.2 N NaOH in 0.5 M HEPES).
Active TGF-β1 by ELISA and functional mink lung epithelial cell (MLEC) assay based on activation of plasminogen activator inhibitor-1 promoter. Active TGF-β1 was measured as above using the ELISA method but without pretreating the plasma sample with acid. The percentage of active TGF-β1 was calculated by dividing the active TGF-β1 value by the total value and multiplying by 100. TGF-β1 activity was also measured as previously described by a functional bioassay, 22 using a mink lung epithelial cell (MLEC) line stably expressing a luciferase reporter gene under the control of the plasminogen activator inhibitor-1 promoter (kindly provided by Dr. Daniel Rifkin, NYU School of Medicine, NY).
Development of a high-sensitivity single-molecule counting assay (SMCA) to measure active TGF-β1 in human plasma samples. Because the ELISA assay did not detect any active TGF-β1 in plasma from healthy controls, we developed a more sensitive TGF-β1 assay using the Singulex Erenna SMCA technology (EMD Millipore). We first tested the binding affinity of 5 antibodies from R&D Systems (2 mAb, MAB240, and MAB2401; 2 rabbit polyclonal antibodies [R3066 and R3102] against peptide sequences corresponding to mature TGF-β1; and a chicken polyclonal antibody [AF-101]) to bioactive recombinant TGF-β1 (240-B) using surface plasmon resonance 23 (Blitz System, Forte Bio). Each of the first 4 antibodies was immobilized on the tip of a biosensor chip surface using protein G, and the chicken polyclonal IgY was immobilized by biotinylating it and binding it to a streptavidin chip. The binding affinity of TGF-β1 was determined as a percentage of white light passage.
We then screened antibody pairs with a sandwich assay. Monoclonal antibodies were used as capture agents, and both monoclonal and polyclonal antibodies were used for detection. After initial testing, we labeled the capture antibodies with biotin and bound them to streptavidincoated magnetic microparticle beads (MPs). We labeled the detection antibodies with fluorescent dye AF-647 according to the manufacturer's instructions (Erenna capture and detection reagent labeling kits; EMD Millipore).
After the best antibody pair was selected, neat plasma samples (100 µL) or serially-diluted TGF-β1 standards (200-B; R&D Systems) were incubated with 100 µL of MPs (12.5 µg) coated with capture antibody and incubated for 120 minutes at 25°C in a 96-well plate without shaking to avoid shear activation of TGF-β1. After washing once, 20 µL of detection antibody was added and incubated for 60 minutes at 25°C with shaking. After 4 washes, 10 µL of elution buffer was added and incubated for 5 minutes at 25°C with shaking. Eluates containing the fluorescent dye-labeled detection antibody were separated from the MPs with a magnet and transferred to a 384-well plate containing 10 µL neutralization buffer. Signal light was generated from a laser and measured by a confocal microscope and a photon detector. When the signal is low, these photons can be counted as single events. At high analyte concentrations, an algorithm computes the total sum of all photons to improve assay sensitivity and extend the dynamic measuring range 1-3 orders of magnitude greater than possible with traditional immunoassay technologies. The final signal, termed "detected events" (DEs), represents the sum of all such measured events. The second output, termed photon events (PEs), represents the sum of all photons counted in all DEs. This measure was used at higher concentrations where there was a significant probability that 2 molecules would pass through the detector in the same 1-ms counting bin. At the highest concentrations of analyte, PEs began to saturate, and total photons (TPs), the sum of all PEs and background, was used. DE, PE, and TP signals were used to generate a weighted 4-parameter logistic curve fit for each signal type. To estimate the concentration of an unknown, the DE, PE, and TP signals were plotted as 3 weighted 4-parametric logistic curves to obtain a linear regression curve from which the concentrations were interpolated as described by Todd et al. 24 The inter-and intra-assay coefficient of variation (CV) was determined to assess the reliability and reproducibility of the assay. The specificity of the assay was assessed by determining the effect of neutralizing TGF-β1 with an anti-TGF-β1 antibody or a recombinant construct containing the TGF-β receptor fused to an immunoglobulin Fc domain (Fc-TGFβRII, CR&D, 341BR).
Quantitation of high molecular weight vWf multimers from
in-gel vWf multimer analysis. The loss of high molecular weight (HMW) von Willebrand factor (vWf) multimers has been associated with conditions in which there is elevated intravascular shear, including aortic stenosis and LVAD implantation, and thus loss of HMW multimers may be considered a surrogate marker for in vivo shear. [25] [26] [27] [28] So, to assess the effect of shear generated by LVAD, the HMW multimeric structure of vWf was studied by discontinuous sodium dodecylsulfate-agarose gel electrophoresis as described by Studt et al., 29 with some modifications. To avoid potential selective loss of the higher molecular weight multimers during conventional electrophoretic transfer immunoblotting, multimers were analyzed directly in the gel using anti-vWf antibody. In brief, gels were fixed after electrophoresis with 10% acetic acid and 25% isopropanol, washed thoroughly with Tris-buffered saline containing 1% bovine serum albumin (TBS), and incubated with rabbit polyclonal anti-vWF antibody (Dako) for 3 hours at RT. Gels were washed with TBS with Tween 20 4 times and incubated with goat anti-rabbit IgG-conjugated with the fluorophore IRDye-680RD (LI-COR). Gels were washed with TBS 4 additional times, and in-gel immunoreactivity bands were quantified using an image analysis program (LI-COR Odyssey). Band intensities were quantified using the ImageJ program (National Institutes of Health) and expressed as a percentage of the total intensity of all of bands in each sample. HMW-vWf multimers were defined as those above the 10th identifiable band, starting from the cathodal (+) position.
STATISTICAL METHODS
Statistical calculations were performed using R version 2.1.12 (R-project.org). For comparisons between cases and controls, demographic characteristics were tabulated using summary statistics. All TGF-β1 and TSP-1 values for patient samples were log-normally distributed, and so the values were log10-transformed for analysis. Linear models were used to compare LVAD patients with healthy control with age and gender as covariates. The differences between LVAD (pre/post) and controls were assessed via contrast using Student's t test. Changes after LVAD in the longitudinal cohort were assessed using a mixed effect model with a random intersect and time (pre/ post) as a factor. Univariate correlation among continuous values was assessed using Pearson correlation coefficient. Data are shown as median (interquartile range), mean ± standard deviation (SD), or mean ± standard error of mean. P value ≤0.05 on 2-sided tests was considered significant.
RESULTS
Preanalytic phase optimization of human plasma sample preparation and quality control measurements for in vitro platelet activation. We investigated the effect of different methods of blood drawing and plasma preparation on total TGF-β1 levels in healthy volunteers using the ELISA method (Fig 1) . When blood samples were collected into syringes containing sodium citrate and plasma was prepared by centrifuging blood at 3,000 g for 15 minutes at RT (Fig 1, A) within 5 minutes of blood drawing, the total TGF-β1 levels were 2.75 ± 1.2 ng/mL (mean ± SD) (n = 6). When the platelet activation inhibitor PGE1 was added to the blood before centrifugation, the TGF-β1 levels were~50% lower (1.3 ± 0.3 ng/mL; P = 0.008), suggesting that the difference between these values was because of in vitro release of TGF-β1 from platelets during plasma preparation. To avoid in vitro release of TGF-β1 without the need to add PGE 1, we tested a number of different combinations of centrifugation speed and temperature. The lowest levels of TGF-β1, 0.9 ± 0.4 ng/mL, were obtained when citrated blood was immediately centrifuged at 12,000 g for 5 minutes at 4°C (n = 6; P = 0.001 vs the above method without PGE1 and P = 0.2 vs the above method with PGE1). Plasma prepared by the rapid centrifugation method at 4°C from blood drawn into vacuum tubes containing sodium citrate gave values similar to those obtained with blood collected into syringes containing sodium citrate (0.8 ± 0.2 ng/mL in vacuum tubes and 0.8 ± 0.5 ng/mL in syringes [n = 5; P = 0.4]). Active TGF-β1 could not be detected by ELISA in any of the plasma samples from the healthy volunteers.
The effect of different anticoagulants on TGF-β1 levels in plasma prepared from blood collected into vacuum tubes by immediate centrifugation at 12,000 g for 5 minutes at 4°C is shown in Fig 1, B . Tubes containing sodium citrate gave the lowest levels of total TGF-β1 (0.9 ± 0.4 ng/mL; n = 18) compared with tubes containing ethylenediaminetetraacetic acid (1.4 ± 0.5 ng/mL; n = 13), heparin (2.0 ± 0.9 ng/mL; n = 9), or citrate, theophylline, adenosine, and dipyridamole (1.4 ± 0.7 ng/ mL; n = 8). Active TGF-β1 was not detected in any of these samples by ELISA. The effect of storing blood collected into vacuum tubes containing sodium citrate at RT for 2 hours before centrifugation, with or without PGE1, was also assessed (Fig 1, C) . Plasma levels of total TGF-β1 were 0.87 ± 0.3 ng/mL in samples prepared immediately (0 hours) after blood drawing, and significantly higher in samples kept at RT for 2 hours in the absence of PGE1 (1.7 ± 0.5 ng/mL, n = 10; P < 0.001). Adding PGE1 immediately after blood drawing in samples kept at RT for 2 hours (2 hours + PGE1) resulted in intermediate TGF-β1 levels (1.1 ± 0.4 ng/mL; P = 0.024 compared with plasma samples prepared after 2 hours, and P = 0.1 compared with samples centrifuged immediately [n = 10]).
To assess in vitro release of other platelet α-granule contents, we also tested plasma levels of PF4 and TSP-1 antigens by immunoblotting samples prepared immediately or kept at RT for 2 hours without PGE1. The samples kept at RT for 2 hours contained variable amounts of PF4 and TSP-1 as judged by their respective staining intensities. In sharp contrast, PF4 and TSP-1 antigens were nearly undetectable in samples prepared immediately (Fig 1, D) . Based on these data, we excluded from analysis samples with elevated levels of PF4. We included samples showing an isolated increase in TSP-1 as previous studies indicate that this pattern is likely to reflect in vivo release because much or all of the PF4 released from platelets in vivo binds to endothelial cell glycosaminoglycans.
20,21
Effect of shear on release and activation of platelet TGF-β1 in human plasma samples. We previously demonstrated that shear can activate latent TGF-β1 in thrombinstimulated platelet releasates and in serum, 16 and now tested whether shear can both initiate release of latent TGF-β1 from platelets and then activate the released latent TGF-β1. Subjecting human whole blood collected in 0.38% sodium citrate to a shear rate of 1,800 s −1 for 10 minutes at room temperature led to an increase in total TGF-β1 from 1.4 ± 0.5 ng/mL, to 3.9 ± 0.9 ng/mL, (n = 4; P = 0.02) (Fig 1, E) . TSP-1 and PF4 plasma levels also increased after exposure to shear (data not shown), consistent with an effect of shear on the platelet release reaction as the mechanism of the increased plasma TGF-β1 levels. We then measured active TGF-β1 in the plasma before or after subjecting the plasma to additional shear at 1,800 s −1 for 2 hours at room temperature. We found that shear led to variable, but significant, increases in active TGF-β1 (Fig 1, F) (n = 4; P = 0.05, paired t test). Active TGF-β1 in shear-activated platelet-rich plasma samples was also measured by a cell-based MLEC assay and demonstrated higher PAI-1 luciferase activity in sheared samples compared with unsheared controls (Fig 1, G ; n = 4; P < 0.001, paired t test). The specificity of the assay for active TGF-β1 was assessed with a TGF-β1 neutralizing antibody (AF-101; R&D Systems), and >90% of PAI-1 luciferase activity was found to be neutralized by antibody (Fig 1, G) . The percentage of total TGF-β1 that was activated in the samples in Fig 1, G , was determined by measuring both active and total TGF-β1 using the ELISA and found to be much less than 1% in the unsheared sample, and between 3% and 4% in the sheared sample (Fig 1, H) . Active TGF-β1 measured by the ELISA was strongly correlated with PAI-1 luciferase activity measured by the MLEC-based assay (r = 0.877; P < 0.001).
Development of a high-sensitivity single-molecule counting assay (SMCA) to measure active TGF-β1 in human plasma samples. We found 2 mAbs (MAB240 and MAB2401) that bound to active TGF-β1, but MAB2401 bound with much higher affinity than MAB240 as measured by their dissociation constants (KD) (5.19 × 10 −11 vs 1.59 × 10 −9 M). The polyclonal chicken IgY also bound active TGF-β1 (KD = 1.14 × 10 −9 M), but the 2 polyclonal rabbit antibodies showed minimal binding. MAB240, MAB2401, and the IgY antibody failed to bind to latent TGF-β1 released from platelets after thrombin stimulation. Pairing MAB2401 as capture antibody and the chicken polyclonal IgY as detection antibody gave the best signal-to-noise ratio for detecting active recombinant mature TGF-β1, with lower limits of quantification ranging from 0.5 to 3.9 pg/mL (n = 18) HEPES-modified tyrode's buffer (Fig 2, A) . In parallel assays, the limits of quantification for the ELISA method was much higher, ranging from 5 to 31.25 pg/mL (Fig 2, B) . The standard curves of active TGF-β1 were linear with both assays at higher concentrations, but the SMCA showed better sensitivity and linearity at the lower levels of TGF-β1 (Fig 2, C) . The inter-assay CV was 7.6% and the intraassay CV was calculated to be 5.8% and 7.6% for 2 experimental repeats. The specificity for the active TGF-β1 was validated by incubating samples with a TGF-β1 neutralizing antibody or Fc-TGFβRII, both of which inhibited the measured activity. We also performed a series of quality control assays and found no significant differences in activity with freezing and thawing of samples 3 times and storing samples at RT for up to 2 hours. When active TGF-β1 was added to normal healthy control plasma, the recovery of active TGF-β1 was a function of the input concentration, ranging from 50% at 100 pg/mL to 70% at 10 pg/mL. Most importantly, as Human plasma sample preparation and quality control measurements: (A) Effect of centrifugation speed, duration, and temperature on TGF-β1 release from platelets during plasma preparation. Human plasma samples were prepared by centrifuging citrated blood immediately after collection at 3,000 g for 15 minutes (with or without PGE1) at room temperature (22°C), or at 12,000 g for 5 minutes at 4°C. Total TGF-β1 levels were measured by ELISA (n = 6). Results from individual donors are depicted by the shapes and colors of the points. (B) Plasma samples were prepared from blood collected in vacuum tubes containing sodium citrate (n = 18), EDTA (n = 13), heparin (n = 9), or CTAD (n = 8), by centrifuging the blood at 12,000 g for 5 minutes at 4°C immediately after collection. Results from individual donors are depicted by the colors of the points. (C) Plasma samples were prepared immediately after blood collection (0 hours) or 2 hours after blood collection without (2 hours) or with PGE1 (2 hours + PGE1). (D) Representative immunoblots with antibodies to TSP-1 and PF4 of 2 different plasma samples from healthy controls (1 and 2) prepared immediately (0 hours) or 2 hours after blood collection without (2 hours) or with PGE1 (2 hours + PGE1). (E and F) Effect of shear on release and activation of platelet TGF-β1. (E) Fresh human blood collected in sodium citrate was untreated or subjected to a shear rate of 1,800 s −1 for 10 minutes and then centrifuged at 12,000 g for 5 minutes at 4°C. Plasma was collected, and total TGF-β1 was measured by ELISA (n = 4). (F) Plasma samples prepared from whole blood after 10 minutes of shear from experiment depicted in E were subjected to shear rate of 1,800 s −1 for 2 hours. Active TGF-β1 levels were measured by ELISA (n = 4). (G) Platelet-rich plasma (PRP; prepared by centrifuging citrated blood at 650 g for 4 minutes at room temperature) samples were subjected to a shear rate of 1,800 s −1 for 10 minutes as in E and then centrifuged at 12,000 g for 5 minutes at 4°C. Plasma samples were again subjected to shear rate of 1,800 s −1 for 2 hours, and active TGF-β1 was measured by PAI-1 promoter luciferase reporter construct in MLEC assay; the specificity of the assay was confirmed by the ability of an anti-TGF-β1 antibody (AF-101) to inhibit the PAI-1 luciferase signal (relative luciferase unit [RLU]). (H) Active TGF-β1 levels in the samples in G were also measured by ELISA (n = 4, P < 0.001). Active TGF-β1 measured by MLEC assay and ELISA were positively correlated (r = 0.877; P < 0.001). CTAD, citrate, theophylline, adenosine and dipyridamole; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; MLEC, mink lung epithelial cell; PF4, platelet factor 4; TGF-β1, transforming growth factor-β1; TSP-1, thrombosponidin-1.
proof of principle, the SMCA was able to detect low levels of active TGF-β1 in the plasma of 12 healthy control subjects, whereas these levels were below the sensitivity of the ELISA (Fig 2, D) . The measured values of the control samples based on the standard curve were 5.24 ± 3.8 pg/ mL, but because we recovered only~70% of the active TGF-β1 added to plasma at approximately this concentration, we recognize that the measured values may not reflect the actual values. As a result, we have assigned the mean ± SD of the healthy control samples a value of 100 ± 73% and express the data on the healthy control and patient samples in relationship to this value.
Compared with healthy controls, patients with HF have
higher plasma total TGF-β1 and TSP-1 levels both before and after LVAD implantation. The concentration of total TGF-β1 in the plasma of 20 healthy controls was 1.07 ± 0.60 ng/ mL. In contrast, the level in 19 patients with HF in both the longitudinal and cross-sectional studies tested before LVAD implantation was 3.69 ± 2.5 ng/mL (P < 0.001 vs control). In the 42 patients with HF tested after LVAD implantation (both longitudinal and cross-sectional studies), the levels were 3.92 ± 2.40 ng/mL (P < 0.001 vs control) (Fig 3, A) . The difference between pre-LVAD and post-LVAD values was not statistically significant (P = 0.50). Patients with HF also showed higher TSP-1 levels before and after LVAD implantation (P < 0.001 in both pre-and post-LVAD compared with healthy controls) (Fig 3, B) . Total TGF-β1 levels correlated with TSP-1 levels in both cohort samples (r = 0.90; P < 0.0001; Fig 3, C) , although patients with HF and LVAD with TSP-1 values in the range occupied by the healthy controls had higher total TGF-β1 values than the controls (Fig 3, C) .
Total TGF-β1 levels increase after LVAD implantation in most patients. The mean plasma levels of total TGF-β1 in the 14 patients in the longitudinal study were significantly higher in patients with HF before LVAD implantation (3.76 ± 1.55 ng/mL) than in healthy controls (1.0 ± 0.60 ng/mL; P < 0.001). After LVAD implantation, total TGF-β1 increased to 5.20 ± 2.3 ng/ mL (Fig 4, A ; P = 0.006 vs pre-LVAD), with 12 of 14 patients showing increases. TSP-1 levels followed a similar pattern (Fig 4, B ; P = 0.017; note that TSP-1 data on 2 pre-LVAD and 5 post-LVAD patients are not shown because of technical difficulties in quantifying the TSP-1 bands on immunoblot) and TGF-β1 levels correlated with plasma TSP-1 levels (r = 0.87; P < 0.001) (Fig 4, C) . Four of the 14 patients had thrombi (3 arterial and 1 upper extremity deep venous thrombosis) detected by echocardiography pre-LVAD, and these patients had higher pre-LVAD levels of total plasma TGF-β1 compared with patients without thrombus (Fig 4, D ; P = 0.025). Two patients had documented devicerelated thrombosis leading to device removal, one within the first week and the other within the first month. Both had large increases in TGF-β1 levels when tested within the first week after LVAD insertion (from 3.6 to 8.8 and from 6.7 to 9.9 ng/mL). TSP-1 levels in both patients were also very high, supporting the hypothesis that the high levels of plasma TGF-β1 were due to platelet activation.
Active TGF-β1 levels increase after LVAD implantation in most patients. The 12 healthy controls had lower plasma active TGF-β1 levels measured by the high-sensitivity SMCA than the 14 patients with HF in the longitudinal study (Fig 4, E) . Twelve of the patients with HF had pre-LVAD and 11 had post-LVAD measurements of active TGF-β1. Both the pre-LVAD and the post-LVAD patient samples had higher levels of active TGF-β1 (268 ± 260% of control in pre-LVAD patients and 416 ± 405% of control in the post-LVAD patients) than the healthy controls (100 ± 73% ; Fig 4, E ; P < 0.001). Although active TGF-β1 levels in the post-LVAD samples were higher than in the pre-LVAD samples, the difference was not statistically significant (Fig 4, F ; P = 0.19). Of note, however, 9 of 11 patients had increases in their active TGF-β1 levels, and only 2 had decreases (Fig 4, F) . The latter 2 patients had the highest pre-LVAD levels of active TGF-β1 and developed thrombus in the LVAD.
LVAD implantation is associated with a decrease in HMW-
vWf multimers, and there is a negative correlation between total TGF-β1 and HMW-vWf multimer levels. In-gel immunoblots showed a representative image of vWf multimer sizes and HMW-vWf multimers, defined as Total TGF-β1 levels (ng/mL; log10-transformed values) were higher in patients with HF before and after LVAD implantation than healthy controls (P < 0.001 for both vs healthy controls). The difference between pre-LVAD and post-LVAD values was not significant (P = 0.50). (B) Plasma levels of platelet α-granule protein thrombospondin-1 (TSP-1) were also higher in both pre-and post-LVAD patients than in healthy controls (P < 0.001 for both). (C) Total TGF-β1 values positively correlated with TSP-1 levels (r = 0.90; P < 0.0001). Data shown as mean ± SEM (large gray dot and error bars) and box and whisker plot with solid thick black line indicating the median and the box containing half of the data points. Data were adjusted based on age and gender correction as covariates. HF, heart failure; LVAD, left ventricular assist devices; SEM, standard error of the mean; TGF-β1, transforming growth factor-β1; TSP-1, thrombosponidin-1.
those above the 11th identifiable band, starting from the cathodal position (Fig 5, A) . Representative image quantification showed that HMW-vWf multimers in healthy controls made up 29.5 ± 2.5% of the total multimers (n = 16), whereas patients with HF before LVAD implantation had values of 18.0 ± 10.0%, and patients after LVAD implantation had values of 11.0 ± 9% (Fig 5B, C ; P < 0.001 vs healthy controls and P = 0.007 vs pre-LVAD). The loss of HMW-vWf multimer values correlated negatively with total TGF-β1 levels (Fig 5, D ; r = −0.63; P = 0.023).
DISCUSSION
Our standardized new methods for pre-analytical phase blood drawing and plasma preparation avoid in vitro release of TGF-β1 from platelets and thus allow us to measure plasma TGF-β1 accurately. Moreover, the novel high-sensitive SMCA method of detection we developed allows us to directly measure active TGF-β1. With these techniques, we were consistently able to measure very low levels of active TGF-β1 in control plasma from healthy donors. We detected higher levels of active TGF-β1 in patients with HF compared with healthy controls, with further increases after LVAD implantation, suggesting latent TGF-β1 activation by shear force generated by the LVAD.
There are several potential sources of TGF-β1 that may contribute to cardiac fibrosis associated with HF, including cardiac myocytes, myofibroblasts, fibroblasts, and macrophages. In fact, increased TGF-β1 synthesis has been found in the myocardium of patients with HF due to multiple causes, as well as in a variety of animal models in which HF was induced by ischemia, pressure overload, or vasoactive agents. 30, 31 Under these conditions, TGF-β1 is presumably acting in an (E) Active TGF-β1 levels, measured by single-molecule counting assay (SMCA), were higher in patients with HF pre and post LVAD implantation than healthy controls (P < 0.001 for both pre-and post-LVAD vs healthy controls). (F) Individual patient active TGF-β1 levels in the longitudinal cohort. Levels increased in 9 of 11 patients and decreased in 2 of 11 patients. ELISA, enzyme-linked immunosorbent assay; HF, heart failure; LVAD, left ventricular assist devices; TGF-β1, transforming growth factor-β1; TSP-1, thrombosponidin-1.
autocrine and/or paracrine manner. Platelets are an additional potential source of TGF-β1 because they contain 40-100 times more TGF-β1 than other cells, and they can release it when activated. 32 We previously showed that platelets make a major contribution to plasma TGF-β1 levels in mice, 18 a conclusion that is consistent with studies of patients with immune thrombocytopenia treated with thrombopoietic agents. 33 Plasma TGF-β1 has the potential to act systemically and thus may work independently or in concert with locally synthesized TGF-β1. This is supported by our demonstration that mice with targeted deletion of TGF-β1 in megakaryocytes and platelets have an approximately 40% decrease in plasma TGF-β1 and are partially protected against the development of cardiac hypertrophy, fibrosis, and systolic dysfunction in response to transverse aortic constriction. 18 The elevation of TSP-1 values in the patients with HF both before and after LVAD insertion, and the correlation between TSP-1 and TGF-β1 values, suggest that platelets are at least one of the likely contributors. This conclusion is consistent with previous studies indicating that HF, even in the absence of LVAD insertion, is associated with platelet activation and release of platelet granule contents. [34] [35] [36] Of note, however, pre-LVAD patients with HF with TSP-1 plasma levels in the control range had elevated levels of total TGF-β1, suggesting that additional sources of TGF-β1 are likely contributing to the elevated plasma levels. The heart itself is a potential source because studies of heart tissue from patients with HF showed increased levels of TGF-β1 expression or protein. 31, 37 LVAD insertion could potentially have opposing effects on plasma TGF-β1. By improving cardiac function, it could decrease the platelet activation associated with HF. Alternatively, the shear produced by the pump could directly activate platelets, leading to release of TGF-β1. 38 The increased shear could also activate the released TGF-β1 because we previously demonstrated that the shear generated by several different methods results in TGF-β1 activation in human platelet releasates and serum, 16 and in the current study we found that exposing whole blood to a shear rate of 1,800 s −1 resulted in increases in both total and active TGF-β1. We found that LVAD insertion was associated with modest increases in both TSP-1 and TGF-β1 in most, but not all patients, suggesting that LVAD effects on platelet and TGF-β1 activation dominated any effect on improving cardiovascular function. Moreover, data demonstrating that myocardial TGF-β1 levels are elevated in patients with LVADs suggest that the hemodynamic benefits of LVAD insertion may not reverse the increase in myocardial TGF-β1 associated with HF. 39 Our finding of increased TSP-1 and TGF-β1 in the plasma of patients with HF before LVAD insertion raises the question as to the basis for the platelet activation in HF. Acquired von Willebrand syndrome because of loss of HMW-vWf multimers is commonly observed after LVAD insertion and is presumed to be due to high shear produced by the LVAD, causing selective deposition of the HMW-vWf multimers on shear-activated platelets and/ or activation of ADAMTS-13, the plasma enzyme that digests vWf multimers. [25] [26] [27] [28] Loss of HMW-vWf multimers may, therefore, be a surrogate indicator of increased intravascular shear. As a result, it is of note that 11 of 14 patients with HF before LVAD insertion had HMWvWf multimer percentages below the lowest percentage in the healthy population (Fig 5) . Thus, it is possible that despite the reduction in cardiac output associated with HF, the hemodynamic responses result in increased systemic shear, leading to platelet activation. As expected, LVAD insertion was associated with a marked reduction in the percentage of HMW-vWf multimers in most of the patients with HF who had normal or near-normal basal levels. Overall, there was a strong inverse relationship between HMW-vWf multimer percentages and plasma total TGF-β1 levels. We did not, however, find a significant correlation between HMW-vWf multimers and active TGF-β1 levels, suggesting that factors other than shear may contribute to these levels, including variations in the clearance of active TGF-β1, which has been reported to have a half-life of <2 minutes in the circulation. 40 Whether active TGF-β1 in the circulation of patients with HF contributes to the pathophysiology of the syndrome remains to be investigated, but cardiac fibrosis is an important component of HF and TGF-β1 is known to increase collagen deposition in model systems. 1, [41] [42] [43] [44] [45] [46] Similarly, whether TGF-β1 contributes to any of the complications of LVAD insertion remains unknown, but aortic valve cusp fusion is associated with increased matrix and fibrosis, which are characteristic responses to TGF-β1. 47 On the other hand, TGF-β1 has also been reported to inhibit neutrophil integrin activation in a manner similar to that of growth differentiation factor 15, which has been reported to have cardioprotective effects in experimental models of myocardial infarction. 48 Although LVADs have tremendously improved the quality of life in patients with HF and increased survival time, 49, 50 they still pose high risks of complications, including thrombosis and bleeding. [50] [51] [52] [53] The development of biomarkers predictive of these LVAD-associated complications would, therefore, be desirable. Elevated systemic levels of both total and active TGF-β1 have been reported in a number of human disorders, 2,4-6,9,54 but the dramatic variance in basal plasma levels of TGF-β1 reported in controls (ranging from <0.1 to >60 ng/mL) 4, 13 indicates the lack of standardization and quality control. Based on the results of our previous study in mice, we have developed standardized methods of blood drawing Patients with HF have lower levels of high molecular weight vWf (HMW-vWf) multimers than healthy controls, and these levels decrease further after LVAD implantation. (A) Plasma vWf multimers were analyzed by running plasma samples in discontinuous 1.2% agarose gel electrophoresis followed by direct in-gel fluorescent anti-vWf monoclonal antibody binding and detection by imaging (upper panel) and densitometry (lower panel). HMW-vWf multimers were defined as the area under the curve of all multimers above the 11th multimer (starting from the cathodal end), expressed as a percentage of the area under the curve of all multimers. (B) Representative images of vWf multimer immunoblots of plasma from a healthy subject and patients with HF before (pre-) and after (post-)LVAD implantation. (C) Loss of HMWvWf multimers was observed in the longitudinal study patients with HF before and after LVAD implantation (P = 0.0072). (D) Total TGF-β1 values (expressed as log TGF-β1) were negatively correlated with HMW-vWf multimer sizes when assessing all patients (r = 0.63; P < 0.001). HF, heart failure; LVAD, left ventricular assist devices; TGF-β1, transforming growth factor-β1; vWf, von Willebrand factor. and plasma preparation in humans that minimize in vitro release of platelet granule contents, including TGF-β1. 18 We have also developed plasma sample quality control indicators based on the release of platelet contents, as judged by elevations of both TSP-1 and PF4, given that the majority of the PF4 released from platelets is likely to bind to endothelial cell glycosaminoglycans in vivo. 20, 21 Anecdotal evidence from individual patients in our study suggest that TGF-β1 and TSP-1 may be valuable surrogate markers for in vivo platelet activation associated with thrombosis because patients with pre-LVAD mural thrombi had the highest pre-LVAD total TGF-β1 levels, and patients who subsequently developed thrombosis in their LVADs had very high total plasma TGF-β1 levels 1 week post LVAD implantation, correlating with high levels of circulating TSP-1. These findings suggest in vivo platelet activation due to thrombus formation. Additional longitudinal studies will be required, however, to fully assess whether serial measurements of total TGF-β1 or TSP-1 can improve the therapy of patients with HF or LVADs. Because gastrointestinal bleeding due to arteriovenous malformations is a common complication of LVAD implantation; 55 genetic abnormalities in TGF-β1 receptors and elevated TGF-β1 levels have been associated with hereditary hemorrhagic telangiectasia; 56 and increased nasal mucosal hypervascularity has been reported in patients with HF with and without LVADs, 55 it is interesting to speculate on the possibility that elevated plasma TGF-β1 levels in HF contribute to the development of vascular abnormalities and gastrointestinal bleeding.
In summary, we report the establishment of methods that reliably measure latent and active TGF-β1 in plasma samples without the confounding effects of in vitro release and activation of TGF-β1 from platelets. We also demonstrate that HF and LVAD implantation are associated with increased levels of total TGF-β1, and that these increases correlate inversely with HMW-vWf multimers, an indicator of in vivo shear. This study also raises the possibility that accurate measurements of plasma TGF-β1 levels may serve as a surrogate biomarker of thrombotic complications in patients with HF with LVADs, 57 as well as other disorders associated with platelet activation and/or tissue fibrosis. [4] [5] [6] 9 AUTHOR CONTRIBUTIONS J.A., B.S.C., and D.M. conceived of the study, designed the study, interpreted the data, and drafted the manuscript. D.M. collected patient samples; D.M., J.A., J.M., R.V., and J.G. performed the experiments; and M.S.F. performed the statistical analysis.
